Monday, 10 Dec 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
15 Jun 2018 News High Biologic Blood Levels Increases the Risk of Infections in RA
15 Jun 2018 ACR Video Dr. Olga Petryna at EULAR 2018 - Biologics Don't Affect Infection with Arthroplasty
15 Jun 2018 Social RT @CreakyJoints: US physicians are more prone to continue biologics through pregnancy. Per a research poster presented at #EULAR2018 https…
15 Jun 2018 ACR Video Dr. Artie Kavanaugh at EULAR 2018 - Biosimilar Switching Studies
14 Jun 2018 Social RT @jomargwhite: MTX associated with reduction of CVD risk in patients reviving biologic treatment #eular2018 #methotrexate https://t.co/sl…
14 Jun 2018 Social RT @RajkiranDudam: Do s and Dont's before think of switching to biosimilars #EULAR2018 https://t.co/a8QYnORzER
14 Jun 2018 Social RT @DrJuanOvalles: Promising results with folistatin gene therapy for sporadic inclusion body Myositis. A significant improvement of functi…
14 Jun 2018 News Biosimilar Data at #EULAR2018
14 Jun 2018 News Abbvie Highlights Upadacitinib Trials at EULAR18
13 Jun 2018 Social RT @philipcrobinson: A phase IIB study of UCBs new anti-IL-17 drug bimekizumab that neutralises both IL17 A and F showed good results, can’…
13 Jun 2018 News Vedolizumab Implicated in Exacerbations of SpA in IBD Patients
13 Jun 2018 Social RT @FerreiraRJO: Excellent talk from Tracy French about how nurses can promote shared decision making with patients being proposed to switc…
12 Jun 2018 News JAK Inhibition in Autoinflammatory Syndromes Interferonopathies
12 Jun 2018 Social Humira patent life in EU ends ~Oct 2018; and thus many strange biosimilar names from Amgen (Amgevita, Solymbi), Boehringer Ingelheim (Cyltezo), Samsung (Imraldi) & soon Sandoz (Halimatoz, Hefiya, Hyrimoz) https://t.co/3oDdRnt0Bj
12 Jun 2018 Social Biosimilar overview for patients https://t.co/0dK0KcbzV9
06 Jun 2018 Social The FDA has a new Video Series on Biosimilars https://t.co/7BXdztDta5 - The Promise: new options, $ competition - The Basics: key terms & concepts - Interchangeability: defining the standard - The Development: abbreviated licensure path - The Data: analytics & approval process
05 Jun 2018 Social CORRONA registry study >45k pts shows betw 2002-2013 biologic use in RA & PsA rose to 62% & 52%, with significantly improved measures (CDAI, HAQ), but 35% & 25% of RA & PsA continued w/ moderate/high disease activity. https://t.co/4pO3kTvTre
05 Jun 2018 Social FDA approves Mylans biosimilar version of Neulasta (pegfilgrastim), named Fulphila. Indicated to decrease infection risk associated with febrile neutropenia in patients with non-myeloid cancer on myelosuppressive chemotherapy https://t.co/7CXKPLSNrl
29 May 2018 Social RT @LCalabreseDO: Interesting study by a careful group of Irish investigators on new biologic approach to GCA- needs f/u!! Ustekinumab: N…
29 May 2018 Social RT @ARD_BMJ: Good overview in @NEJM of the reality of #biosimilars- highly relevant to the current rheumatology landscape https://t.co/BjUb…